• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NCI

NCI

NCI Inc Class A NCIT

Last Price$19.95Day Change (%)0.00%
Open Price$19.95Day Change ($)0.00
Day Range19.90–19.9552-Week Range10.98–21.40

As of Fri 7/21/2017 5:33:00 PM | USD

  1. NCI (NCIT ) SHAREHOLDER ALERT - Andrews & Springer LLC is Seeking More Cash for Shareholders of NCI , Inc.

    NCI ( NCIT ) SHAREHOLDER ALERT - Andrews & Springer LLC is Seeking More Cash for Shareholders of NCI , Inc.

  2. Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

    Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

  3. NCI to Be Acquired by H.I.G. Capital, LLC

    NCI to Be Acquired by H.I.G. Capital, LLC

  4. Shareholder Alert: Ademi & O’Reilly, LLP Investigates Whether NCI , Inc. Has Obtained a Fair Price in Its Sale to OceanFirst Financial Corp.

    Shareholder Alert: Ademi & O’Reilly, LLP Investigates Whether NCI , Inc. Has Obtained a Fair Price in Its Sale to OceanFirst Financial Corp.

  5. NCI agrees to be acquired by H.I.G. Capital for about $283 million in cash

    NCI agrees to be acquired by H.I.G. Capital for about $283 million in cash

  6. NCI , INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

    NCI , INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

  7. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of NCI , Inc. to H.I.G. Capital, LLC for $20.00 Per Share is Fair to Shareholders

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of NCI , Inc. to H.I.G. Capital, LLC for $20.00 Per Share is Fair to Shareholders

  8. Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute

    Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute

  9. BlackRock Reports Second Quarter 2017 Diluted EPS of $5.22, or $5.24 as adjusted

    BlackRock Reports Second Quarter 2017 Diluted EPS of $5.22, or $5.24 as adjusted

12345

©2017 Morningstar Advisor. All right reserved.